HER2-Positive Breast Cancer Market By Treatment Type (Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy and Others), By Route of Administration (Parenteral, Oral and Others), By Application (Hospital, Biotechnology & Pharmaceuticals company, Specialty Clinics, Research & Academic Institution and Others), By Distribution Channel ( Hospital pharmacy, Retail pharmacy and Online pharmacy) and By Region - Market Trends, Analysis, and Forecast till 2030

HER2-Positive Breast Cancer Market accounted for USD 8.0 Billion in 2020 and is estimated to be USD 12.3 Billion by 2030 and is anticipated to register a CAGR of 4.3%.

HER2-positive breast cancer treatment refers to a type of breast cancer in which a test revealed the presence of the protein human epidermal growth factor receptor 2 (HER2), which influences cancer cell proliferation. Anyone who has been diagnosed with breast cancer should be examined for the presence of HER2. HER2-positive tumours (also known as HER2-positive tumours) were previously linked to an increased risk of recurrence and mortality from breast cancer.

The prognosis of HER2-positive breast tumours has significantly improved with the use of chemotherapy and targeted treatment against HER2. The term "neoadjuvant therapy" refers to treatment provided prior to surgery with the intention of shrinking the tumour before it is removed. The term "adjuvant therapy" refers to treatment provided after surgery with the purpose of eradicating any cancer cells that may have survived (and potentially spread).

Growth in business operations by emerging and small sized players

The expansion of this industry is due to emerging markets and significant investment in research & development. The rise in cases of HER2-positive breast cancer around the world has influenced the demand for novel medications for HER2-positive breast cancer therapy, which has fueled the expansion of the HER2-positive breast cancer treatment market. Furthermore, high immunotherapy acceptance and favourable reimbursement are seen as encouraging signs for the treatment of HER2-positive breast cancer. The market for HER2-positive breast cancer treatment is thought to be limited by high treatment costs and the cancellation of late-stage clinical trials.

HER2-Positive Breast Cancer market is segmented based on Treatment type, Route of Administration, Application, Distribution channel and Region.

On the basis of Treatment type, the HER2-Positive Breast Cancer market is segmented into Targeted therapy, Chemotherapy, Endocrine therapy, Immunotherapy and Others. Based on Route of Administration, the target market is segmented into Parenteral, Oral and Others. On the basis of Application, the target market is segmented into Hospitals, Biotechnology & Pharmaceutical company, Specialty Clinics, Research & Academic Institution and Others. By Distribution channel, the target market is segmented into Hospital pharmacy, Retail pharmacy and Online pharmacy.

Regional Insights:

On region the HER2-Positive Breast Cancer market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America will hold the largest market share for HER2-positive breast cancer therapy in the upcoming forecast era, followed by Europe, because of the growth in incidences of HER2-positive breast cancer and favourable government regulations as well as advanced healthcare facilities. Due to increased government initiatives and quickly expanding disposable income, Asia-Pacific has emerged as the fastest growing geographic category in terms of sales.

HER2-Positive Breast Cancer Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the HER2-Positive Breast Cancer market report based on treatment type, route of administration, application, distribution channel and region.

HER2-Positive Breast Cancer Market, By Region:

• North America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • U.S.
  • Canada

The key players operating in the HER2-Positive Breast Cancer market includes Pfizer Inc., Eli Lilly and Company, Immunomedics, AstraZeneca, F. Hoffmann-La Roche Ltd, Radius pharmaceuticals, Merck & Co., Inc, Bayer AG, GlaxoSmithKline plc, Syndax pharmaceuticals, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceuticals Industries Ltd, Baxter, Mylan N.V., and Fresenius Kabi AG among others.

Recent News:

• In January 2024, AstraZeneca India Pharma Ltd., a science-led biopharmaceutical company officially launched Trastuzumab deruxtecan, therapy tailored for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer for those who have previously received an anti-HER2 regimen. Developed in collaboration with Daiichi Sankyo, Trastuzumab deruxtecan is a specifically engineered HER2-directed antibody drug conjugate (ADC).

• Pfizer, Inc.
• Eli Lilly and Company
• Immunomedics
• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Radius pharmaceuticals
• Merck & Co. Inc
• Bayer AG
• GlaxoSmithKline plc
• Syndax pharmaceuticals
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Teva Pharmaceuticals Industries Ltd
• Baxter
• Mylan N.V.
• Fresenius Kabi AG
• Others.